Published in
Elsevier, European Journal of Cancer, (51), p. S664-S665, 2015
DOI: 10.1016/s0959-8049(16)31822-6
Links
Tools
3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
Journal article published in 2015 by
J. Larkin,
V. Chiarion-Sileni 
,
R. Gonzalez,
J. J. Grob,
C. L. Cowey,
C. D. Lao,
J. Wagstaff,
D. Hogg,
A. Hill,
M. S. Carlino,
P. Wolter,
C. Lebbé,
J. Schachter,
L. Thomas,
J. C. Hassel
and other authors.
,
R. Gonzalez,
J. J. Grob,
C. L. Cowey,
C. D. Lao,
J. Wagstaff,
D. Hogg,
A. Hill,
M. S. Carlino,
P. Wolter,
C. Lebbé,
J. Schachter,
L. Thomas,
J. C. Hassel
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 